BFRA Tiesioginiai signalai | Didinkite pelną su Getagraph.com

Live Chart Being Loaded With Signals

Commentary (1 saus. 1970 @ 03:00):

Stats
Šios dienos apimtis	4 951.00
Vidutinė apimtis	30 523.00
Rinkos kapitalizacija	0.00
EPS	$0 ( 2022-04-11 )
Last Dividend	$0.104 ( 2021-02-24 )
Next Dividend	$0 ( N/A )
P/E	-4.35
ATR14	$0.324 (12.13%)

Tūris Koreliacija

Ilgas: 0.02 (neutral)

Trumpas: -0.25 (neutral)

Signal:(42.752) Neutral

Biofrontera AG Koreliacija

10 Labiausiai teigiamai susiję koreliacijos
SOHU	0.914
CHB	0.904
NWL	0.904
CSSEP	0.903
TSRI	0.902
AOUT	0.902
HPK	0.9
BMRA	0.897
MODV	0.897
OGI	0.895

10 Labiausiai neigiamai susiję koreliacijos
APXI	-0.914
WINV	-0.908
FRSG	-0.907
KAII	-0.906
ZEUS	-0.906
MLAI	-0.905
MATW	-0.904
ALSA	-0.904
MSAC	-0.903
PTOC	-0.903

Ar žinojote?

Koreliacija yra statistinis rodiklis, aprašantis ryšį tarp dviejų kintamųjų. Jis svyruoja nuo -1 iki 1, kur -1 reiškia tobulo neigiamo ryšio koreliaciją (padidėjus vienam kintamajam, sumažėja kitas), 1 reiškia tobulo teigiamo ryšio koreliaciją (padidėjus vienam kintamajam, padidėja ir kitas), o 0 reiškia jokios koreliacijos (tarp kintamųjų nėra jokio ryšio).

Koreliacija gali būti naudojama analizuojant bet kurių dviejų kintamųjų ryšį, ne tik akcijų. Jis dažnai naudojamas finansų, ekonomikos, psichologijos ir kitose srityse.

Biofrontera AG Koreliacija - Valiuta/Žaliavos

-0.78
( moderate negative )

-0.69
( moderate negative )

0.77
( moderate )

-0.78
( moderate negative )

-0.26
( neutral )

0.47
( neutral )

Biofrontera AG Finansinės ataskaitos

Annual	2020
Pajamos:	$30.35M
Bruto pelnas:	$26.81M (88.35 %)
EPS:	$-0.467

FY	2020
Pajamos:	$30.35M
Bruto pelnas:	$26.81M (88.35 %)
EPS:	$-0.467

FY	2019
Pajamos:	$31.27M
Bruto pelnas:	$26.39M (84.41 %)
EPS:	$-0.312

FY	2018
Pajamos:	$21.11M
Bruto pelnas:	$16.66M (78.91 %)
EPS:	$-0.389

Financial Reports:

No articles found.

Biofrontera AG Dividends

(Q3/22)	(Q4/22)	(Q1/23)	(Q2/23)	(Q3/23)	(Q4/23)	(Q1/24)	(Q2/24)	(Q3/24)	(Q4/24)
$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)

Biofrontera AG Dividend Information - No Dividend Player

Dividend Sustainability Score: 0 - low (50.00%) | Divividend Growth Potential Score: 0 - No dividend growth expected in the near future

Information

First Dividend	$0.0221	2020-03-18
Last Dividend	$0.104	2021-02-24
Next Dividend	$0	N/A
Payout Date	2021-03-04
Next Payout Date	N/A
# dividends	2	--
Total Paid Out	$0.126	--
Avg. Dividend % Per Year	0.19%	--
Score	0.6	--
Div. Sustainability Score	0
Div.Growth Potential Score	0
Div. Directional Score	0	--

Next Divdend (Est)
(2025-01-06)

$0 Estimate 0.00 %

Dividend Stability

0.03 Very Bad

Dividend Score

0.60

Pay Frequency

Annually

Yearly Payout

Year	Amount	Yield
2020	$0.0221	0.22%
2021	$0.104	1.30%
2022	$0	0.00%
2023	$0	0.00%
2024	$0	0.00%

Dividend Commentary

The company does not currently pay dividends. Given its current dividend status and a low Dividend Growth Potential Score (DGPS), there's minimal likelihood of dividends being initiated soon. Considering all factors, the near-term dividend outlook for the company remains unpromising.

Top 10 dividend Companies for NASDAQ

Symbol	Title	Last dividend	Frequency	Years Dividend	Yearly Dividend	Score
OXLC	Dividend Royal	2023-12-14	Monthly	14	10.00%	8.50
OXSQ	Dividend Diamond	2023-12-14	Monthly	21	9.10%	8.50
PSEC	Dividend Royal	2023-12-26	Monthly	21	7.04%	8.50
SLVO	Dividend Royal	2023-11-20	Monthly	12	10.77%	8.50
QYLD	Dividend Royal	2023-11-20	Monthly	11	7.50%	8.50
GAIN	Dividend Royal	2023-12-04	Monthly	20	8.19%	8.50
GLDI	Dividend Royal	2023-11-20	Monthly	12	7.15%	8.50
HRZN	Dividend King	2023-12-18	Monthly	15	6.60%	8.45
USOI	Dividend Royal	2023-11-20	Monthly	8	16.70%	8.28
PFLT	Dividend King	2023-11-15	Monthly	14	6.50%	8.27

Dividend Sustainability Score (DSS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
netProfitMarginTTM	-0.429	1.500	-8.58	-10.00	[0 - 0.5]
returnOnAssetsTTM	-0.231	1.200	-7.70	-9.24	[0 - 0.3]
returnOnEquityTTM	-1.503	1.500	-10.00	-10.00	[0.1 - 1]
payoutRatioTTM	0	-1.000	0	0	[0 - 1]
currentRatioTTM	3.15	0.800	10.00	8.00	[1 - 3]
quickRatioTTM	2.48	0.800	0.0937	0.0750	[0.8 - 2.5]
cashRatioTTM	1.997	1.500	0.0174	0.0262	[0.2 - 2]
debtRatioTTM	0.423	-1.500	2.94	-4.42	[0 - 0.6]
interestCoverageTTM	-2.47	1.000	-2.03	-2.03	[3 - 30]
operatingCashFlowPerShareTTM	-0.102	2.00	-0.0341	-0.0683	[0 - 30]
freeCashFlowPerShareTTM	-0.130	2.00	-0.0651	-0.130	[0 - 20]
debtEquityRatioTTM	3.24	-1.500	10.00	-10.00	[0 - 2.5]
grossProfitMarginTTM	0.883	1.000	10.00	10.00	[0.2 - 0.8]
operatingProfitMarginTTM	-0.251	1.000	-7.02	-7.02	[0.1 - 0.6]
cashFlowToDebtRatioTTM	-0.119	1.000	-1.774	-1.774	[0.2 - 2]
assetTurnoverTTM	0.538	0.800	9.75	7.80	[0.5 - 2]
Total Score				-0.244

Dividend Growth Score (DGS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
peRatioTTM	-5.33	1.000	-0.640	0	[1 - 100]
returnOnEquityTTM	-1.503	2.50	-10.00	-10.00	[0.1 - 1.5]
freeCashFlowPerShareTTM	-0.130	2.00	-0.0434	-0.130	[0 - 30]
dividendYielPercentageTTM	0	1.500	0	0	[0 - 0.4]
operatingCashFlowPerShareTTM	-0.102	2.00	-0.0341	-0.0683	[0 - 30]
payoutRatioTTM	0	1.500	0	0	[0 - 1]
pegRatioTTM	-2.28	1.500	-10.00	0	[0.5 - 2]
operatingCashFlowSalesRatioTTM	-0.0939	1.000	-4.85	0	[0.1 - 0.5]
Total Score				-2.56

Biofrontera AG

Biofrontera AG, a biopharmaceutical company, engages in the development and commercialization of pharmaceutical products for the treatment of dermatological conditions and diseases caused primarily by exposure to sunlight that results in sun damage to the skin. Its principal product is Ameluz, a prescription drug for the treatment of lesion-directed and field-directed actinic keratosis. The company also offers BF-RhodoLED lamp, a photodynamic therapy for lesion-directed and field-directed treatment of actinic keratosis; and Belixos, an over-the-counter line of skin care cosmetic products. In addition, it is developing Ameluz for the treatment of field cancerization and nodular basal cell carcinoma. Further, the company's product portfolio includes Xepi, a prescription antibiotic cream for the treatment of impetigo; and Aktipak, a generic drug for the treatment of acne. It offers its products primarily in the United States, Europe, and Israel. The company has a collaboration and partnership agreement with Maruho Co., Ltd. Biofrontera AG was founded in 1997 and is headquartered in Leverkusen, Germany.